Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The industry rank for Adaptive Biotechnologies's 14-Day RSI or its related term are showing as below:
FRA:1HM's 14-Day RSI is ranked worse than 83.87% of 217
companies
in the Medical Diagnostics & Research industry
Industry Median: 47.7
vs FRA:1HM: 62.65
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Adaptive Biotechnologies 14-Day RSI Related Terms
FRA:1HM vs GRAL, WGS, RDNT: 14-Day RSI Comparison
For the Diagnostics & Research subindustry, Adaptive Biotechnologies's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adaptive Biotechnologies 14-Day RSI vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Adaptive Biotechnologies's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Adaptive Biotechnologies's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adaptive Biotechnologies (FRA:1HM) has a 14-Day RSI of 62.65 as of Jul. 24, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Adaptive Biotechnologies and its competitors. According to the industry distribution chart, Adaptive Biotechnologies ranks #182 out of 217 companies in the Medical Diagnostics & Research industry, placing it in the top 83.9%.
Is Adaptive Biotechnologies' 14-Day RSI too high?
Adaptive Biotechnologies' current 14-Day RSI is 62.65. The Medical Diagnostics & Research industry median 14-Day RSI is 47.70. Adaptive Biotechnologies' value of 62.65 is 31.3% above this industry median. Based on the distribution chart, Adaptive Biotechnologies ranks #182 out of 217 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Adaptive Biotechnologies has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adaptive Biotechnologies' 14-Day RSI compare to GRAL and WGS?
According to the Medical Diagnostics & Research industry distribution chart, Adaptive Biotechnologies ranks #182 out of 217 companies for 14-Day RSI. This places Adaptive Biotechnologies in the lower half of its industry. The industry median 14-Day RSI is 47.70. Adaptive Biotechnologies' value of 62.65 is 31.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Medical Diagnostics & Research company?
The median 14-Day RSI among Medical Diagnostics & Research companies is 47.70, based on 217 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Adaptive Biotechnologies's current 14-Day RSI of 62.65 is 31.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Adaptive Biotechnologies and its competitors. For the Medical Diagnostics & Research industry, the median 14-Day RSI is 47.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adaptive Biotechnologies's current 14-Day RSI is 62.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptive Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, Adaptive Biotechnologies (FRA:1HM) is currently considered Significantly Overvalued. The stock's GF Value™ is €8.88, compared to a current price of €19.76 — trading 122.5% above its estimated fair value. The current 14-Day RSI is 62.65 and 31.3% above the Medical Diagnostics & Research industry median of 47.70. Adaptive Biotechnologies' overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Adaptive Biotechnologies (FRA:1HM), the current 14-Day RSI is 62.65 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adaptive Biotechnologies (FRA:1HM) Overvalued in 2026?
Based on GuruFocus' analysis, Adaptive Biotechnologies stock appears to be overvalued.
The current stock price of €19.76 is trading 122.5% above its estimated GF Value™ of €8.88.
GuruFocus considers Adaptive Biotechnologies to be Significantly Overvalued.
Key valuation signals for FRA:1HM:
14-Day RSI: 62.65
GF Value™: €8.88 vs. price of €19.76 (122.5% above fair value)
Industry Position: 31.3% above the Medical Diagnostics & Research median (#182 of 217)
No single metric tells the full story. See the FRA:1HM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
68GF Score
Get the complete analysis for FRA:1HM
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1HM has been successfully added to your 
